The Wall Street Journal (assinante clique aqui) que médicos americanos evitam Avandia e, ao mesmo tempo prescrevem mais Actos (pioglitazone). Há uma grande chance que a maioria dos pacientes, ao invés da prescrição de um desses dois medicamentos se beneficiaria mais de outras condutas com redução radical de peso, aumento da atividade física, redução dos níveis de pressão arterial e de colesterol. Por isso, talvez não seja mudança adequada, somente conveniente a quem prescreve. Abaixo parte do texto.
U.S. Doctors Shun Glaxo MedicineIn Wake of Study
LONDON -- Doctors in the U.S. have shunned GlaxoSmithKline PLC's diabetes drug Avandia since a study was published last week linking the drug to greater heart-attack risk, according to early prescription data. Market-intelligence group Impact RX said Avandia's share of the market for newly prescribed oral antidiabetics fell to around zero from around 10% in the two days after the article was published in the New England Journal of Medicine on May 21. At the same time, the rate of patients switching from one drug to another was three times the usual level. Takeda Pharmaceutical Co.'s rival drug, Actos, saw its share of the new-prescription market increased to 22% from 10%. The U.K. company played down the data, saying, "Two days of data is not enough to reach sensible conclusions on the trend for Avandia new prescriptions."
Nenhum comentário:
Postar um comentário